{"id":"NCT03252431","sponsor":"EVIVE Biotechnology","briefTitle":"Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","officialTitle":"A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, NeulastaÂ® Active-Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-12","primaryCompletion":"2019-09-25","completion":"2020-03-05","firstPosted":"2017-08-17","resultsPosted":"2021-05-07","lastUpdate":"2023-07-03"},"enrollment":393,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer","Neutropenia"],"interventions":[{"type":"DRUG","name":"F-627","otherNames":[]},{"type":"DRUG","name":"Neulasta","otherNames":["pegfilgrastim"]}],"arms":[{"label":"F-627","type":"EXPERIMENTAL"},{"label":"Neulasta","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, multi-center, single dose, open-label and Neulasta controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with Stage I - III invasive breast cancer receiving chemotherapy treatment.","primaryOutcome":{"measure":"Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1","timeFrame":"The first of 4, 21-day chemotherapy cycles (average 3 weeks)","effectByArm":[{"arm":"F-627","deltaMin":0.2,"sd":0.51},{"arm":"Neulasta","deltaMin":0.2,"sd":0.45}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":197},"commonTop":["Bone pain","Asthenia","Leukocytosis","Arthralgia"]}}